Q-omics provides the consensus-scored RNF151 profile across patient tissues and cancer cell-line models. RNF151 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RNF151 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, RNF151 RNA expression shows 9,647 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where RNF151 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNF151 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNF151 survival associations across molecular data types. RNF151 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNF151 RNA expression–survival associations across cancer types. High RNF151 expression shows unfavorable associations in KIRC, ACC, KICH and LIHC, but favorable associations in HNSC and CHOL. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for RNF151 RNA expression.
This table summarizes RNF151 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for RNF151. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNF151 shows lower tumor expression in PAAD and higher tumor expression in COAD, LIHC, LUAD, UCEC and BLCA. The COAD box plot shows higher RNF151 RNA expression in tumor versus normal tissue (log2 FC = +0.088, t-test p = .001).
This table shows molecular features associated with RNF151 in patient tissues and cancer cell lines. In patient samples, RNF151 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RNF151 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
